Summary of Literature Use of PSMA PET for Evaluation of Primary Renal Lesions
| Author | Number of primary renal lesions | Study design | Radiotracer | Histology | Average SUVmax of primary tumor | Average lesion to background SUVmax |
| Sawicki et al. (2017) (18) | 5 | Retrospective | 68Ga-PSMA | 3 ccRCC, 1 pRCC, 1 chRCC | 9.9 ± 9.2 (range 1.7–27.2) | 0.2 ± 0.3 (range, 0.02–0.7) |
| Rhee et al. (2016) (15) | 10 | Prospective | 68Ga-PSMA-11 (HBED-CC) | 8 ccRCC, 1 pRCC, 1 unclassified | 18.0 (range 3.7–36.5) | N/A |
| Siva et al. (2017) (17) | 8 | Retrospective | 68Ga-PSMA-11 (HBED-CC) | 7 ccRCC, 1 pRCC | 8.6 (range, 0–26.5) | N/A |
| Golan et al. (current study) | 29 | Prospective | 68Ga-PSMA-11 (HBED-CC) | 18 ccRCC, 4 pRCC 2 chRCC, 1 nephroma, 2 angiomyolipomas 2 oncocytoma | Malignant: 10.6 ± 6.2 (range, 1.5–22); Benign: 3.8 ± 1.2 (range, 2–5.4) | Malignant: 1.5 ± 1 (range, 0.2–6); Benign: 0.4 ± 0.2 (range, 0.3–0.6) |
N/A = not applicable.